| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000020409 |
| Receipt No. | R000023557 |
| Official scientific title of the study | Effect of nutritional vitamin D supplements in hemodialysis patients |
| Date of disclosure of the study information | 2015/12/31 |
| Last modified on | 2017/03/10 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Effect of nutritional vitamin D supplements in hemodialysis patients
|
|
| Title of the study (Brief title) | Nutritional vitamin D supplementation in hemodialysis patients | |
| Region |
|
|
| Condition | |||
| Condition | CKD-5D | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To investigate the serum 25(OH)D level in hemodialysis patients. Additionally, to assess the effects of supplementation in hemodialysis patients with nutritional vitamin D.
|
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Serum 25(OH)D and 1,25(OH)2D levels at 6 and 12 months after the beginning of supplementation of nutritional vitamin D. |
| Key secondary outcomes | Serum calcium, phosphorus, albumin, and intact parathyroid hormone levels, CRP(C-reactive protein) levels, Serum fibroblast growth factor 23 (FGF 23)levels, hemoglobin (Hb) levels,
changes in blood pressure, medication use (erythrocyte-stimulating agents, activated vitamin D) |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | No treatment |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 3 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Ingestion of ergocalciferol (vitamin D2, which comes from plant sources), 400 IU daily for 6 months of the first half, and continue to take it at the same dose for 6 months of the latter half. | |
| Interventions/Control_2 | Ingestion of ergocalciferol (vitamin D2, which comes from plant sources), 400 IU daily for 6 months of the first half, and continue to take it at the same dose, additionally oral cholecalciferol (vitamin D3, which comes from animal sources), 7000 IU weekly for 6 months of the latter half. | |
| Interventions/Control_3 | Control group | |
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. hemodialysis patients
2. Subjects who agree to participate in the current study with a written informed consent |
|||
| Key exclusion criteria | 1. Subjects who are at risk of having allergic reactions to drugs or supplements
2. Subjects who regularly take nutritional vitamin D |
|||
| Target sample size | 40 | |||
| Research contact person | |
| Name of lead principal investigator | Masanori Okamoto |
| Organization | Saiseikai Wakayama Hospital |
| Division name | Kidney Center |
| Address | 12 banchou 45, Wakaya, Japan |
| TEL | 073-424-5185 |
| mokamoto@wakayama-med.ac.jp | |
| Public contact | |
| Name of contact person | Masanori Okamoto |
| Organization | Saiseikai Wakayama Hospital |
| Division name | Kidney Center |
| Address | 12 banchou, Wakayama, Japan |
| TEL | 073-424-5185 |
| Homepage URL | |
| mokamoto@wakayama-med.ac.jp | |
| Sponsor | |
| Institute | Saiseikai Wakayama Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Social Welfare Organization Saiseikai Imperial Gift Foundation, Inc |
| Organization | |
| Division | |
| Category of Funding Organization | Non profit foundation |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | Division of Nephrology, Wakayama Medical University, Japan |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000023557 |